<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03260647</url>
  </required_header>
  <id_info>
    <org_study_id>MAMBO</org_study_id>
    <nct_id>NCT03260647</nct_id>
  </id_info>
  <brief_title>Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction in Gynecological Cancers</brief_title>
  <acronym>MAMBO</acronym>
  <official_title>Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction (MAMBO) Program for Women With Advanced Gynecological Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Management of Malignant Bowel Obstruction (MBO) in Patients with Advanced Gynecological&#xD;
      Cancers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Guidelines for the management of patients with Malignant Bowel Obstruction(MBO) are not&#xD;
      available and as such, there remains an urgent need for a collaborative approach to&#xD;
      streamline patient care and optimize use of hospital resources. This study will focus on&#xD;
      management of MBO in advanced gynecological cancers.If patients with MBO can be effectively&#xD;
      managed in an ambulatory setting, this may improve quality and consistency of patient care,&#xD;
      and help reduce volume and duration of bed occupancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Optimization of multidisciplinary care</measure>
    <time_frame>2 years</time_frame>
    <description>To optimize the multidisciplinary care management of MBO in patients with advanced gynecological cancer treated at University Health Network (UHN) which include in-patient and ambulatory management algorithm for MBO&#xD;
• Measured by a ratio of days alive and out of hospital compare to days in hospital within the first 60 days after diagnosis of MBO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the treatment outcomes of patients with MBO&#xD;
Measured by resolution of MBO and overall survival&#xD;
Measured by transition through specific bowel management colour code system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of impact of MBO management on hospital visits</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the impact of MBO management on number of emergency room visits, hospital admission and number of days alive and outside of hospital within the first 168 days (6 months) after the diagnosis of MBO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of impact of MBO management on patient reported outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the impact of ambulatory MBO management on patient reported outcomes using the Distress Assessment &amp; Response Tool (DART)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate nutritional status of patients with MBO</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the nutritional status of patients with MBO&#xD;
• Measured by monthly albumin and weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinico-pathological factors</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the clinico-pathological factors that may predict benefit from palliative surgery, chemotherapy and total parenteral nutrition (TPN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improve patient understanding and awareness of MBO</measure>
    <time_frame>2 years</time_frame>
    <description>To improve patients' understanding and awareness of MBO with patient education material.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine percentage number of patient microbiome sample analyses completed</measure>
    <time_frame>1.5 years</time_frame>
    <description>To record the percentage of patients who agree to, and for whom sample collection and analysis is completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record changes in the sum and types of gut microbiome from baseline to study end</measure>
    <time_frame>1.5 years</time_frame>
    <description>Changes in the sum as well as types of microbiomes as recorded at baseline, initiation of total parenteral nutrition, incidence of an MBO and end of study are to be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate cannabis use in patient population</measure>
    <time_frame>1.5 years</time_frame>
    <description>Assess for any relationship between cannabis use and MBO</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gynecologic Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Management algorithm for Malignant Bowel Obstruction</intervention_name>
    <description>a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients with MBO who undergo palliative procedures or surgical intervention will be offered&#xD;
      optional consent for tissue collection for research. Fresh-frozen and formalin-fixed&#xD;
      paraffin-embedded (FFPE) tumour tissue specimens, as well as ascites will be collected for&#xD;
      translational studies. Stool samples will be collected for microbiome analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with gynecological cancer and at risk or presently having Malignant bowel&#xD;
        obstruction (MBO)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically and /or cytologically confirmed gynecological cancer, including ovarian,&#xD;
        fallopian tube, endometrial, cervical or primary peritoneal cancer Deemed to be at risk of&#xD;
        developing or have a clinical diagnosis of MBO as defined using the following criteria:&#xD;
        clinical evidence of bowel obstruction (history/physical/radiological examination; and&#xD;
        bowel obstruction beyond the ligament of Treitz.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no specified exclusion criteria for this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Lheureux</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie L'heureux</last_name>
    <phone>416-946-2818</phone>
    <phone_ext>2818</phone_ext>
    <email>stephanie.lheureux@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Carey</last_name>
    <email>ruth.carey@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Oza</last_name>
      <phone>416-946-2818</phone>
      <email>amit.oza@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Janany Sivalingam</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2640</phone_ext>
      <email>janany.sivalingam@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Lheureux, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Tran E, Spiceland C, Sandhu NP, Jatoi A. Malignant Bowel Obstruction in Patients With Recurrent Ovarian Cancer. Am J Hosp Palliat Care. 2016 Apr;33(3):272-5. doi: 10.1177/1049909114566225. Epub 2014 Dec 31.</citation>
    <PMID>25552305</PMID>
  </reference>
  <reference>
    <citation>Mooney SJ, Winner M, Hershman DL, Wright JD, Feingold DL, Allendorf JD, Neugut AI. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol. 2013 Apr;129(1):107-12. doi: 10.1016/j.ygyno.2012.12.028. Epub 2012 Dec 26.</citation>
    <PMID>23274561</PMID>
  </reference>
  <reference>
    <citation>Sartori E, Chiudinelli F, Pasinetti B, Maggino T. Bowel obstruction and survival in patients with advanced ovarian cancer: analysis of prognostic variables. Int J Gynecol Cancer. 2009 Jan;19(1):54-7. doi: 10.1111/IGC.0b013e318198ff4b. No abstract available.</citation>
    <PMID>19258942</PMID>
  </reference>
  <reference>
    <citation>Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21.</citation>
    <PMID>24767708</PMID>
  </reference>
  <reference>
    <citation>Martin-Lorente C, Mackay H, Lafromboise L, et al: Retrospective review of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC), International Journal of Gynecological Cancer, 2015, pp 1434-1435</citation>
  </reference>
  <reference>
    <citation>Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J, Herbst A, Smart E, Krouse RS. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage. 2007 Jul;34(1 Suppl):S49-59. doi: 10.1016/j.jpainsymman.2007.04.011. Epub 2007 Jun 4.</citation>
    <PMID>17544243</PMID>
  </reference>
  <reference>
    <citation>Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, Gemlo B, Hunt TM, Krebs HB, Mercadante S, Schaerer R, Wilkinson P; Working Group of the European Association for Palliative Care. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001 Jun;9(4):223-33. doi: 10.1007/s005200000198.</citation>
    <PMID>11430417</PMID>
  </reference>
  <reference>
    <citation>Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012;4:159-69. doi: 10.2147/CMAR.S29297. Epub 2012 Jun 13.</citation>
    <PMID>22904637</PMID>
  </reference>
  <reference>
    <citation>Daniele A, Ferrero A, Fuso L, Mineccia M, Porcellana V, Vassallo D, Biglia N, Menato G. Palliative care in patients with ovarian cancer and bowel obstruction. Support Care Cancer. 2015 Nov;23(11):3157-63. doi: 10.1007/s00520-015-2694-9. Epub 2015 Mar 25.</citation>
    <PMID>25805450</PMID>
  </reference>
  <reference>
    <citation>Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008 May;44(8):1105-15. doi: 10.1016/j.ejca.2008.02.028. Epub 2008 Mar 21.</citation>
    <PMID>18359221</PMID>
  </reference>
  <reference>
    <citation>Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2016 Jan 4;2016(1):CD002764. doi: 10.1002/14651858.CD002764.pub2.</citation>
    <PMID>26727399</PMID>
  </reference>
  <reference>
    <citation>Feuer DJ, Broadley KE, Shepherd JH, Barton DP. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(4):CD002764. doi: 10.1002/14651858.CD002764.</citation>
    <PMID>11034757</PMID>
  </reference>
  <reference>
    <citation>Furnes B, Svensen R, Helland H, Ovrebo K. Challenges and outcome of surgery for bowel obstruction in women with gynaecologic cancer. Int J Surg. 2016 Mar;27:158-164. doi: 10.1016/j.ijsu.2016.02.002. Epub 2016 Feb 4.</citation>
    <PMID>26853847</PMID>
  </reference>
  <reference>
    <citation>Levy M, Smith T, Alvarez-Perez A, Back A, Baker JN, Beck AC, Block S, Dalal S, Dans M, Fitch TR, Kapo J, Kutner JS, Kvale E, Misra S, Mitchell W, Portman DG, Sauer TM, Spiegel D, Sutton L, Szmuilowicz E, Taylor RM, Temel J, Tickoo R, Urba SG, Weinstein E, Zachariah F, Bergman MA, Scavone JL. Palliative Care Version 1.2016. J Natl Compr Canc Netw. 2016 Jan;14(1):82-113. doi: 10.6004/jnccn.2016.0009.</citation>
    <PMID>26733557</PMID>
  </reference>
  <reference>
    <citation>Kolomainen DF, Daponte A, Barton DP, Pennert K, Ind TE, Bridges JE, Shepherd JH, Gore ME, Kaye SB, Riley J. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol. 2012 Apr;125(1):31-6. doi: 10.1016/j.ygyno.2011.11.007. Epub 2011 Nov 12.</citation>
    <PMID>22082991</PMID>
  </reference>
  <reference>
    <citation>Mangili G, Aletti G, Frigerio L, Franchi M, Panacci N, Vigano R, DE Marzi P, Zanetto F, Ferrari A. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):830-5. doi: 10.1111/j.1525-1438.2005.00144.x.</citation>
    <PMID>16174232</PMID>
  </reference>
  <reference>
    <citation>Goto T, Takano M, Aoyama T, Miyamoto M, Watanabe A, Kato M, Sasaki N, Hirata J, Sasa H, Furuya K. Outcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy. Oncol Lett. 2012 Nov;4(5):883-888. doi: 10.3892/ol.2012.835. Epub 2012 Jul 30.</citation>
    <PMID>23162616</PMID>
  </reference>
  <reference>
    <citation>Kucukmetin A, Naik R, Galaal K, Bryant A, Dickinson HO. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev. 2010 Jul 7;2010(7):CD007792. doi: 10.1002/14651858.CD007792.pub2.</citation>
    <PMID>20614464</PMID>
  </reference>
  <reference>
    <citation>Bryan DN, Radbod R, Berek JS. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):125-34. doi: 10.1111/j.1525-1438.2006.00283.x.</citation>
    <PMID>16445622</PMID>
  </reference>
  <reference>
    <citation>Diver E, O'Connor O, Garrett L, Boruta D, Goodman A, Del Carmen M, Schorge J, Mueller P, Growdon W. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol. 2013 May;129(2):332-5. doi: 10.1016/j.ygyno.2013.02.002. Epub 2013 Feb 8.</citation>
    <PMID>23402902</PMID>
  </reference>
  <reference>
    <citation>Chouhan J, Gupta R, Ensor J, Raghav K, Fogelman D, Wolff RA, Fisch M, Overman MJ. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016 Feb;5(2):239-47. doi: 10.1002/cam4.587. Epub 2015 Dec 29.</citation>
    <PMID>26714799</PMID>
  </reference>
  <reference>
    <citation>Abu-Rustum NR, Barakat RR, Venkatraman E, Spriggs D. Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. Gynecol Oncol. 1997 Mar;64(3):493-5. doi: 10.1006/gyno.1996.4605.</citation>
    <PMID>9062158</PMID>
  </reference>
  <reference>
    <citation>Li M, Macedo A, Crawford S, Bagha S, Leung YW, Zimmermann C, Fitzgerald B, Wyatt M, Stuart-McEwan T, Rodin G. Easier Said Than Done: Keys to Successful Implementation of the Distress Assessment and Response Tool (DART) Program. J Oncol Pract. 2016 May;12(5):e513-26. doi: 10.1200/JOP.2015.010066. Epub 2016 Apr 5.</citation>
    <PMID>27048610</PMID>
  </reference>
  <reference>
    <citation>Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, Moore RG, Granai CO. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol. 2006 Oct;103(1):176-80. doi: 10.1016/j.ygyno.2006.02.013. Epub 2006 Mar 27.</citation>
    <PMID>16564074</PMID>
  </reference>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>April 24, 2023</last_update_submitted>
  <last_update_submitted_qc>April 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03260647
org study id: MAMBO
nct id: NCT03260647
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Management of Malignant Bowel Obstruction (MBO) in Patients with Advanced Gynecological
      Cancers
Guidelines for the management of patients with Malignant Bowel Obstruction(MBO) are not
      available and as such, there remains an urgent need for a collaborative approach to
      streamline patient care and optimize use of hospital resources. This study will focus on
      management of MBO in advanced gynecological cancers.If patients with MBO can be effectively
      managed in an ambulatory setting, this may improve quality and consistency of patient care,
      and help reduce volume and duration of bed occupancy.
observational model: Case-Only
time perspective: Prospective
measure: Optimization of multidisciplinary care
time frame: 2 years
description: To optimize the multidisciplinary care management of MBO in patients with advanced gynecological cancer treated at University Health Network (UHN) which include in-patient and ambulatory management algorithm for MBO
• Measured by a ratio of days alive and out of hospital compare to days in hospital within the first 60 days after diagnosis of MBO
measure: Evaluation of treatment outcomes
time frame: 2 years
description: To evaluate the treatment outcomes of patients with MBO
Measured by resolution of MBO and overall survival
Measured by transition through specific bowel management colour code system
measure: Evaluation of impact of MBO management on hospital visits
time frame: 2 years
description: To evaluate the impact of MBO management on number of emergency room visits, hospital admission and number of days alive and outside of hospital within the first 168 days (6 months) after the diagnosis of MBO
measure: Evaluation of impact of MBO management on patient reported outcomes
time frame: 2 years
description: To evaluate the impact of ambulatory MBO management on patient reported outcomes using the Distress Assessment & Response Tool (DART)
measure: To evaluate nutritional status of patients with MBO
time frame: 2 years
description: To evaluate the nutritional status of patients with MBO
• Measured by monthly albumin and weight
measure: Evaluation of clinico-pathological factors
time frame: 2 years
description: To evaluate the clinico-pathological factors that may predict benefit from palliative surgery, chemotherapy and total parenteral nutrition (TPN)
measure: Improve patient understanding and awareness of MBO
time frame: 2 years
description: To improve patients' understanding and awareness of MBO with patient education material.
measure: Determine percentage number of patient microbiome sample analyses completed
time frame: 1.5 years
description: To record the percentage of patients who agree to, and for whom sample collection and analysis is completed
measure: Record changes in the sum and types of gut microbiome from baseline to study end
time frame: 1.5 years
description: Changes in the sum as well as types of microbiomes as recorded at baseline, initiation of total parenteral nutrition, incidence of an MBO and end of study are to be recorded
measure: Evaluate cannabis use in patient population
time frame: 1.5 years
description: Assess for any relationship between cannabis use and MBO
intervention type: Other
intervention name: Management algorithm for Malignant Bowel Obstruction
description: a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
Patients with MBO who undergo palliative procedures or surgical intervention will be offered
      optional consent for tissue collection for research. Fresh-frozen and formalin-fixed
      paraffin-embedded (FFPE) tumour tissue specimens, as well as ascites will be collected for
      translational studies. Stool samples will be collected for microbiome analysis
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: Female
gender based: Yes
gender description: Female
minimum age: 18 Years
maximum age: 100 Years
healthy volunteers: No
last name: Stephanie Lheureux
role: Principal Investigator
affiliation: University Health Network, Toronto
last name: Stephanie L'heureux
phone: 416-946-2818
phone ext: 2818
email: stephanie.lheureux@uhn.ca
last name: Ruth Carey
email: ruth.carey@uhn.ca
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
country: Canada
citation: Tran E, Spiceland C, Sandhu NP, Jatoi A. Malignant Bowel Obstruction in Patients With Recurrent Ovarian Cancer. Am J Hosp Palliat Care. 2016 Apr;33(3):272-5. doi: 10.1177/1049909114566225. Epub 2014 Dec 31.
PMID: 25552305
citation: Mooney SJ, Winner M, Hershman DL, Wright JD, Feingold DL, Allendorf JD, Neugut AI. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol. 2013 Apr;129(1):107-12. doi: 10.1016/j.ygyno.2012.12.028. Epub 2012 Dec 26.
PMID: 23274561
citation: Sartori E, Chiudinelli F, Pasinetti B, Maggino T. Bowel obstruction and survival in patients with advanced ovarian cancer: analysis of prognostic variables. Int J Gynecol Cancer. 2009 Jan;19(1):54-7. doi: 10.1111/IGC.0b013e318198ff4b. No abstract available.
PMID: 19258942
citation: Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21.
PMID: 24767708
citation: Martin-Lorente C, Mackay H, Lafromboise L, et al: Retrospective review of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC), International Journal of Gynecological Cancer, 2015, pp 1434-1435
citation: Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J, Herbst A, Smart E, Krouse RS. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage. 2007 Jul;34(1 Suppl):S49-59. doi: 10.1016/j.jpainsymman.2007.04.011. Epub 2007 Jun 4.
PMID: 17544243
citation: Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, Gemlo B, Hunt TM, Krebs HB, Mercadante S, Schaerer R, Wilkinson P; Working Group of the European Association for Palliative Care. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001 Jun;9(4):223-33. doi: 10.1007/s005200000198.
PMID: 11430417
citation: Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012;4:159-69. doi: 10.2147/CMAR.S29297. Epub 2012 Jun 13.
PMID: 22904637
citation: Daniele A, Ferrero A, Fuso L, Mineccia M, Porcellana V, Vassallo D, Biglia N, Menato G. Palliative care in patients with ovarian cancer and bowel obstruction. Support Care Cancer. 2015 Nov;23(11):3157-63. doi: 10.1007/s00520-015-2694-9. Epub 2015 Mar 25.
PMID: 25805450
citation: Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008 May;44(8):1105-15. doi: 10.1016/j.ejca.2008.02.028. Epub 2008 Mar 21.
PMID: 18359221
citation: Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2016 Jan 4;2016(1):CD002764. doi: 10.1002/14651858.CD002764.pub2.
PMID: 26727399
citation: Feuer DJ, Broadley KE, Shepherd JH, Barton DP. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(4):CD002764. doi: 10.1002/14651858.CD002764.
PMID: 11034757
citation: Furnes B, Svensen R, Helland H, Ovrebo K. Challenges and outcome of surgery for bowel obstruction in women with gynaecologic cancer. Int J Surg. 2016 Mar;27:158-164. doi: 10.1016/j.ijsu.2016.02.002. Epub 2016 Feb 4.
PMID: 26853847
citation: Levy M, Smith T, Alvarez-Perez A, Back A, Baker JN, Beck AC, Block S, Dalal S, Dans M, Fitch TR, Kapo J, Kutner JS, Kvale E, Misra S, Mitchell W, Portman DG, Sauer TM, Spiegel D, Sutton L, Szmuilowicz E, Taylor RM, Temel J, Tickoo R, Urba SG, Weinstein E, Zachariah F, Bergman MA, Scavone JL. Palliative Care Version 1.2016. J Natl Compr Canc Netw. 2016 Jan;14(1):82-113. doi: 10.6004/jnccn.2016.0009.
PMID: 26733557
citation: Kolomainen DF, Daponte A, Barton DP, Pennert K, Ind TE, Bridges JE, Shepherd JH, Gore ME, Kaye SB, Riley J. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol. 2012 Apr;125(1):31-6. doi: 10.1016/j.ygyno.2011.11.007. Epub 2011 Nov 12.
PMID: 22082991
citation: Mangili G, Aletti G, Frigerio L, Franchi M, Panacci N, Vigano R, DE Marzi P, Zanetto F, Ferrari A. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):830-5. doi: 10.1111/j.1525-1438.2005.00144.x.
PMID: 16174232
citation: Goto T, Takano M, Aoyama T, Miyamoto M, Watanabe A, Kato M, Sasaki N, Hirata J, Sasa H, Furuya K. Outcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy. Oncol Lett. 2012 Nov;4(5):883-888. doi: 10.3892/ol.2012.835. Epub 2012 Jul 30.
PMID: 23162616
citation: Kucukmetin A, Naik R, Galaal K, Bryant A, Dickinson HO. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev. 2010 Jul 7;2010(7):CD007792. doi: 10.1002/14651858.CD007792.pub2.
PMID: 20614464
citation: Bryan DN, Radbod R, Berek JS. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):125-34. doi: 10.1111/j.1525-1438.2006.00283.x.
PMID: 16445622
citation: Diver E, O'Connor O, Garrett L, Boruta D, Goodman A, Del Carmen M, Schorge J, Mueller P, Growdon W. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol. 2013 May;129(2):332-5. doi: 10.1016/j.ygyno.2013.02.002. Epub 2013 Feb 8.
PMID: 23402902
citation: Chouhan J, Gupta R, Ensor J, Raghav K, Fogelman D, Wolff RA, Fisch M, Overman MJ. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016 Feb;5(2):239-47. doi: 10.1002/cam4.587. Epub 2015 Dec 29.
PMID: 26714799
citation: Abu-Rustum NR, Barakat RR, Venkatraman E, Spriggs D. Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. Gynecol Oncol. 1997 Mar;64(3):493-5. doi: 10.1006/gyno.1996.4605.
PMID: 9062158
citation: Li M, Macedo A, Crawford S, Bagha S, Leung YW, Zimmermann C, Fitzgerald B, Wyatt M, Stuart-McEwan T, Rodin G. Easier Said Than Done: Keys to Successful Implementation of the Distress Assessment and Response Tool (DART) Program. J Oncol Pract. 2016 May;12(5):e513-26. doi: 10.1200/JOP.2015.010066. Epub 2016 Apr 5.
PMID: 27048610
citation: Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, Moore RG, Granai CO. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol. 2006 Oct;103(1):176-80. doi: 10.1016/j.ygyno.2006.02.013. Epub 2006 Mar 27.
PMID: 16564074
responsible party type: Sponsor
mesh term: Intestinal Obstruction
sharing ipd: No